Characteristics, treatment patterns, healthcare resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims data
Published: 6 June 2023| Version 1 | DOI: 10.17632/994227m9zy.1
Contributors:
Heide A. Stirnadel-Farrant, Xiao Xu, Justin Kwiatek, Priya Jain, Juliana Meyers, Sean Candrilli, Daniel Mines, Catherine J. DattoDescription
Supplementary material
Files
Categories
Autoimmunity, Steroid, Antibiotics, Opioid, Health Care Cost, Pemphigoid, Comorbidity, Disease Burden, Health Care Utilization, Skin Blistering, Bullous Disease
Funding
AstraZeneca (United Kingdom)